Cite
HARVARD Citation
Srivastava, R. et al. (2022). Combined inhibition of BET bromodomain and mTORC1/2 provides therapeutic advantage for rhabdomyosarcoma by switching cell death mechanism. Molecular carcinogenesis. 61 (8), pp. 737-751. [Online].